{"name":"Vyant Bio","slug":"vyant-bio","ticker":"","exchange":"","domain":"","description":"Vyant Bio is a biotechnology company focused on the development of innovative therapies, with a current pipeline that includes VYNT-0126 in Phase 2 clinical trials. The company reported a revenue of $29 million and an R&D spend of $6.772 million as of December 31, 2017, reflecting its commitment to advancing its drug candidates.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":29121000,"revenueGrowth":7.7,"grossMargin":0,"rdSpend":6772000,"netIncome":-22690000,"cash":15205000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQQWVxZlh3S0tzWlpVYXQtXzlGS3R2VFlRWmZrNlZnMU5XbDBGTENsb20wYWVnSWlubEZzM1diZS1Va0xUT2lxaVFHT0RNaHVZMnM0ekJwcThnV0NkVm9uV21UZzAybFBPbmpoUTI0M1pIZVdnNVRmSWdyMHc5WENBXzU4cGxZTXJOSDhQV0dVVlByMGJkVzNJdURJMHg3VHdwNm9GZl9pTzFJdnRmcXRuaFFiMTVjU0VENjhzWkZjRVRibmQ1YWc?oc=5","date":"2024-01-03","type":"pipeline","source":"Louisiana Economic Development - LED (.gov)","summary":"2023 Achievements Marked by New Technologies, Commercialization and Advanced Research - Louisiana Economic Development - LED (.gov)","headline":"2023 Achievements Marked by New Technologies, Commercialization and Advanced Research - Louisiana Economic Development -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE8ySkR4ZndXbDZZVWxmT19JZnN3WlNYVVlsdmRYbGhhVmdveGZIRDg0RldhV3JiUmpORUVuTlU0WXlvT1g0SlVLdGUwZ0U1VjhpS29qSE9UZ0wwVUExbmRtRmphT0JrX0F5RjFZeQ?oc=5","date":"2023-10-31","type":"pipeline","source":"Fierce Biotech","summary":"UPDATED: The 2023 Biotech Graveyard - Fierce Biotech","headline":"UPDATED: The 2023 Biotech Graveyard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQaV8yQmdUdjEzZFV1d2wzZU5CTXZpM1Z3WHZHeUtwSXFjUmZ0V01fVXJ0NFlieXFVMzV3anRqY0pqQVJUTGhvSEU4M2lFeERpMjVPeENFU1dDNlVhdE05a2lOTjhMUVhVakNXY2djU2FPWEYwTkw1LVJMazV2aWNIR1ZXa1k5dy1hLUQ0dmlqc1hrbWUwTE55ckFtaVR5ak5BSTRSdmg5QnE4WnRTMlZtTW9EWlNKYlU0QVY2ZmhB?oc=5","date":"2023-10-25","type":"deal","source":"Pharmaceutical Technology","summary":"AxoSim acquires microBrain technology to build neurological drug pipeline - Pharmaceutical Technology","headline":"AxoSim acquires microBrain technology to build neurological drug pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNbUJGTGdPaW1OVjllSGd4SkdoeExxNURQZFU2c2RHWHNXcS03S0twQWpCM250dHdRVlZpbnVUOWZGb2YwT1ZlSGEyTnplMUtXT0hiYUxuV2NIRkpVbTFNRXpLLW5xaC1KTkR4R2lROTZFazVfcFRma1lDeXNGdVN0Mml0anlqQlpOUy1NZ1BVVWVvd2ZLY3dkeQ?oc=5","date":"2023-10-24","type":"pipeline","source":"Fierce Biotech","summary":"Organoids touted as future of brain disorder R&D as AxoSim scoops up tech from Vyant subsidiary - Fierce Biotech","headline":"Organoids touted as future of brain disorder R&D as AxoSim scoops up tech from Vyant subsidiary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOMkZ4bXgtbGNwYXZESXlxa1FIRENkSlNkZkNQVGRHZ2ZhS2VBTlE3UVlvOWkweHZTLTNKdDNQOW1iNXRndzNxdUo0cU9ma0IzQ0V5aHdEUFZyNHF4OXgwaTdMTnBxWHRiNWU2Mm94RjM1SVZBSURzMlh5VGJPS011YjZGMnRqalJrdEtPY2YzRnJaWXh4S0RKN3YtMWRzQQ?oc=5","date":"2023-07-17","type":"deal","source":"Contract Pharma","summary":"AxoSim Acquires Vyant Bio’s StemoniX Assets for $2.25M - Contract Pharma","headline":"AxoSim Acquires Vyant Bio’s StemoniX Assets for $2.25M","sentiment":"neutral"},{"date":"2023-05-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-04-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2023-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPTFhRZDFibFlLOTZsRHlJX2dkSUVuM2hGZ3phdWhUdWRPbEMtZ2V6cklZeG0xSGF1b2tzVi1IaEVUWXc1bnk0ei1GSi1YSHc2MmhESkJrZnJRMW5lT29EMm9zMmM1dTVEVnVNRjJJLXUtcS1VSlR5Xy1tajJ0c1h4a0RhQl9tdjM0bjk2VldnbWk1V3VTVk5BWWxmYVp2d0xTMFN4RWZ2SUlZbXdweFJSOC03MjQ4Q1FZUFVKag?oc=5","date":"2023-02-10","type":"pipeline","source":"Fierce Biotech","summary":"Faced with safety issues over inflammation drug, AstraZeneca spinout Aristea closes shop - Fierce Biotech","headline":"Faced with safety issues over inflammation drug, AstraZeneca spinout Aristea closes shop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNQmlPbmVPZ013VXFOcDc3RnBwMHMyV1d0WFZIU3JHSnlmU3piWGpmaDVsMXgwSXhycjlSNU1QOWxuSkt4MjZDQWZKUEU2eXdybmk1WUp0LXRqMmxIcTRrQmZSejBsd3lTc0p0MkdTOWt2Y1dhNEVtbmM3TUZaNGRnOEh4U2d1MXNxNkJlVnNSYTM1bXBKVjRKSmlaSS1WSmNiMHZJ?oc=5","date":"2023-02-03","type":"pipeline","source":"Fierce Biotech","summary":"Drug discovery biotech Vyant preps to wind down operations, starting with layoffs - Fierce Biotech","headline":"Drug discovery biotech Vyant preps to wind down operations, starting with layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5OVFUwTjNwUGhnQ19Ba18wTjROOVBiLW1wU0xWVmVuT3EtT3hVd3pOTGFtM3hmd180TmxtSmZjUkRqTXNOdExTOGV1aTJVYk1nRnEyUlkybjBwWThxc1NnS1FwakhYS1pTY0hSNzN6YndDUk1RX3NFbXpOX200a28?oc=5","date":"2022-11-04","type":"deal","source":"Pharmaceutical Technology","summary":"Reaction Biology to acquire Vyant Bio subsidiary’s operations in US - Pharmaceutical Technology","headline":"Reaction Biology to acquire Vyant Bio subsidiary’s operations in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNSlFOTVVmbWs0ME5nOV9DZmNMNEdZZHBVZVAxbkdSNGZBbDR3UFgxTVh3c1o4dEw1M2VoRUI5SWEyS200aWlkS1BWZUowUVpEcWFWclRCbVhnRVl4a256cjdjNkpRa2k3b1dCeVJnZUxWOVpqV0JuWGgtNmtSZzFqcTVrQ2RBUXluMHdVMHp2R2s5ZUduUVI1bEJjTkZOVVVzQjkyTU5xVnlhOXFXTUZkdklPcUNyNVpxUTdaNFZYYjhfZWFJUUE4cXRSS0FIQ2htbzIwckNQSU9nV0hIZmc?oc=5","date":"2022-11-03","type":"pipeline","source":"Proactive financial news","summary":"Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million - Proactive financial news","headline":"Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ESUFwa29HNE1QeEpDNFFnYl9rNHFEekk0Zk5Wem5rbkFZc09lamNKQ1ZFR1JhUG51Q0gzX3FFQnFvU3VLUnRVem5QX2dkUjQzb3d6UDQyUmwtVjBSbE1j?oc=5","date":"2021-11-22","type":"pipeline","source":"Nature","summary":"Transforming drug discovery to get more breakthrough medicines to patients - Nature","headline":"Transforming drug discovery to get more breakthrough medicines to patients","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":29121000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":29121000,"period":"2017-12-31"},{"value":27049000,"period":"2016-12-31"},{"value":27049000,"period":"2016-12-31"},{"value":18040000,"period":"2015-12-31"},{"value":18040000,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":6772000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-22690000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":15205000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}